ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2020
Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis.Liver international : official journal of the International Association for the Study of the Liver · 2025Pooled it
- Novel bile salt analogs reduce lipid accumulation in liver cells with potential to treat both metabolic dysfunction-associated steatotic liver disease and Clostridioides difficile infection.bioRxiv : the preprint server for biology · 2026Article
- The Impact of Steatotic Liver Disease on Cytokine and Chemokine Kinetics During Sepsis.International journal of molecular sciences · 2025Article
- Nonalcoholic Fatty Liver Disease Increases the Risk of Lung Abscess: Findings from a Nationwide Cohort Study.Journal of clinical medicine · 2025Article
- Diabetes Mellitus and the Risk and Outcomes ofInfection and drug resistance · 2025Review
- Steatotic Liver Disease and Sepsis Outcomes-A Prospective Cohort Study (SepsisFAT).Journal of clinical medicine · 2024Article
- Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis.International journal of molecular sciences · 2023Article
- Review
- Nonalcoholic fatty liver disease and non-liver comorbidities.Clinical and molecular hepatology · 2023Review
- The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes.Life (Basel, Switzerland) · 2022Article
- The Role of Non-Alcoholic Fatty Liver Disease in Infections.Life (Basel, Switzerland) · 2022Review
- Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study.Open forum infectious diseases · 2022Article
- Review
- Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized forWorld journal of hepatology · 2021Article
- Article
- 1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease.ERJ open research · 2021Article
- Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for RecurrentAntibiotics (Basel, Switzerland) · 2021Article
- NAFLD and Infection, a Nuanced Relationship.Canadian journal of gastroenterology & hepatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea while nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. The aim of this study was to determine whether NAFLD increases susceptibility to CDI. A retrospective cohort study included patients ≥ 65 years, treated with antimicrobial therapy ≥ 24 h, and hospitalized ≥ 72 h in a 36-month period. Three-hundred fourteen patients were included; 83 with NAFLD and 231 controls. Except for diabetes mellitus (37.35% vs. 25.11%, p = 0.0462) and obesity (18.07% vs. 8.23%, p = 0.0218) that were more frequent in NAFLD group, there were no differences in other comorbidities, hospital admissions, antibiotic therapy within 3 months, prescription, and duration of antibiotic therapy. Fourteen (16.9%) patients with NAFLD and 17 (7.4%) in control group developed in-hospital CDI (p = 0.0156). The Charlson Age-Comorbidity Index > 6 (OR 4.34, 95%CI 1.39-13.57), hospital admission within 3 months (OR 7.14, 95%CI 2.33-21.83), serum albumins < 28 g/L (OR 3.15, 95%CI 1.04-9.53), NAFLD (OR 3.27, 95%CI 1.04-10.35), eGFR < 40 (OR 4.89, 95%CI 1.61-14.88), treatment with piperacillin/tazobactam (OR 4.86, 95%CI 1.59-14.83), and carbapenems (OR 3.99, 95%CI 1.28-12.40) were independently associated with CDI. Our study identified NAFLD as an independent predictor of CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.